The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Open accessAbstract
BACKGROUND: Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. METHODS: In two randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe atopic dermatitis whose disease was inadequately controlled by topical treatment. Patients were randomly assigned in a 1:1:1 ratio to receive, for 16 weeks, subcutaneous dupilumab (300 mg) or placebo weekly or the same dose of dupilumab every other week alternating with placebo. The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator's Global Assessment and a reduction of 2 points or more in that score from baseline at week 16. RESULTS: We enrolled 671 patients in SOLO 1 and 708 in SOLO 2. In SOLO 1, the primary outcome occurred in 85 patients (38%) who received dupilumab every other week and in 83 (37%) who received dupilumab weekly, as compared with 23 (10%) who received placebo (P<0.001 for both comparisons with placebo). The results were similar in SOLO 2, with the primary outcome occurring in 84 patients (36%) who received dupilumab every other week and in 87 (36%) who received dupilumab weekly, as compared with 20 (8%) who received placebo (P<0.001 for both comparisons). In addition, in the two trials, an improvement from baseline to week 16 of at least 75% on the Eczema Area and Severity Index was reported in significantly more patients who received each regimen of dupilumab than in patients who received placebo (P<0.001 for all comparisons). Dupilumab was also associated with improvement in other clinical end points, including reduction in pruritus and symptoms of anxiety or depression and improvement in quality of life. Injection-site reactions and conjunctivitis were more frequent in the dupilumab groups than in the placebo groups. CONCLUSIONS: In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo. Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ; SOLO 2 ClinicalTrials.gov number, NCT02277769 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As neurons express receptors for IL-4 and IL-13, the early improvement of itch upon targeted therapy with dupilumab, tralokinumab or lebrikizumab supports the assumption of a direct effect of these drugs on nerve endings92,96,183.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [183]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two phase 3 trials found dupilumab to significantly improve symptoms and quality of life in patients with AD compared to placebo [39].”
From Atopic dermatitis (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Upadacitinib, a JAK inhibitor with proven efficacy in moderate-tosevere AD 30,31 , and dupilumab, an IL-4Rα antagonist that blocks IL-4/IL-13 signalling 32,33 , were selected.”
From Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation
Boguniewicz, M., & Leung, D. Y. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01027.x · Cited by 1,073
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citation
Cited by
Items 801–900 of 1,002
Hartono, S. P., Chatrath, S., Aktaş, O. N., Kubala, S. A., Capozza, K., Myles, I. A., Silverberg, J. I., & Schwartz, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-59162-9 · Cited by 22
Self-citationNew biologics for allergic diseases
Manka, L. A., & Wechsler, M. E. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1459188 · Cited by 22
“scores, as well as improvement in other validated measures of pruritus, anxiety and depression, and quality of life [54].”
BackgroundSystemic Treatment for Severe Atopic Dermatitis
Bianchi, M. G., & Junior, P. F. G.-B. (2018) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-018-0521-y · Cited by 23
“Side effects described more frequent than in the placebo group were injection site reactions and conjunctivitis (Simpson et al. 2017).”
Therapeutic strategies for eosinophilic dermatoses
Simon, D., & Simon, H. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.01.002 · Cited by 24
Alexander, H., Patton, T., Jabbar‐Lopez, Z. K., Manca, A., & Flohr, C. (2019) · F1000Research · doi:10.12688/f1000research.17039.1 · Cited by 25
Raffi, J., Suresh, R., Fishman, H. A., Botto, N. C., & Murase, J. E. (2019) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2019.10.001 · Cited by 23
Aryl Hydrocarbon Receptor Activation Downregulates IL-33 Expression in Keratinocytes via Ovo-Like 1
Tsuji, G., Hashimoto‐Hachiya, A., Vu, Y. H., Miake, S., Takemura, M., Mitamura, Y., Ito, T., Murata, M., Furue, M., & Nakahara, T. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030891 · Cited by 24
“Recently, it has been reported that treatment with dupilumab, an anti-IL-4 receptor alpha antibody, induces rapid improvement of itch in AD patients [33].”
BackgroundBeck, L. A., Thaçi, D., Deleuran, M. S., de Bruin-Weller, M. S., Chen, Z., Khokhar, F. A., Zhang, M., Ozturk, Z. E., & Shumel, B. S. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1871463 · Cited by 22
Self-citationCurrent Clinical Options for the Management of Itch in Atopic Dermatitis
Lipman, Z. M., Labib, A., & Yosipovitch, G. (2021) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s289716 · Cited by 24
Sevagamoorthy, A., Sockler, P. G., Akoh, C. C., & Takeshita, J. (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2022.2114783 · Cited by 22
Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted Approach
D’Amato, M., Pastore, D., Lupia, C., Candia, C., Bruni, A., Garofalo, E., Longhini, F., Maglio, A., Petrone, A., Vatrella, A., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134749 · Cited by 27
“Regarding comorbidities, when compared to placebo, dupilumab therapy for individuals with moderate-to-severe atopic dermatitis improved subjective symptoms, quality of life scores, sadness, and anxiety scores in addition to objective disease indicators [97].”
Bunick, C. G. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.06.1574 · Cited by 22
Drucker, A. M., Ellis, A. G., Jabbar‐Lopez, Z. K., Yiu, Z. Z. N., Arents, B. W. M., Burton, T., Spuls, P. I., Küster, D., Schmitt, J. M., & Flohr, C. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-023061 · Cited by 23
Atopic dermatitis: a review of evolving targeted therapies
Kalamaha, K., Reis, E., Newton, S. L., Roche, C., Julson, J. R., Fernandes, H., & Rodrigues, J. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1560267 · Cited by 20
“In 2016, SOLO1 and SOLO2 were RCDB phase III studies that contained 671 and 708 moderate to severe AD patients, respectively, from around the world [33].”
BackgroundCurrent and emerging biologic and small molecule therapies for atopic dermatitis
Li, R., Hadi, S. M., & Guttman‐Yassky, E. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1573422 · Cited by 22
“Yet, there are still many patients that do not resolve their AD in full with dupilumab as only ~1/3 of treated patients achieved EASI-90 [50], highlighting the ongoing need for additional treatments tailored to the different AD subsets.”
BackgroundSelf-citationFlorian, P., Flechsenhar, K. R., Bartnik, E., Ding‐Pfennigdorff, D., Herrmann, M., Bryce, P. J., & Nestle, F. O. (2020) · Experimental Dermatology · doi:10.1111/exd.13942 · Cited by 20
The Association Between Mercury Exposure and Atopic Dermatitis in Early Childhood
Shin, J., Kim, B.-M., Ha, M., Park, H., Hong, Y., Kim, Y., Kwon, J. H., & Ha, E. (2019) · Epidemiology · doi:10.1097/ede.0000000000001002 · Cited by 20
Dupilumab in Elderly Patients With Severe Atopic Dermatitis
Russo, F., Milanesi, N., Cartocci, A., Bruzziches, F., Tronconi, G., Lazzeri, L., D’Erme, A. M., Bagnoni, G., Gola, M., Cinotti, É., et al. (2020) · Dermatitis · doi:10.1097/der.0000000000000686 · Cited by 20
Kimura, A., Takeda, A., Ikebukuro, T., & Hori, J. (2021) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-020-00234-y · Cited by 21
“These pathways are involved in B-cell differentiation, immunoglobulin (Ig) E production, and a Th-2dominant immune response [1].”
BackgroundDupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study
Torres, T. R., Lopes, M. J. P., Gonçalo, M., Claro, C., de Oliveira, M. J. R., Gomes, J., Vieira, A. P., Amoedo, P., Alpalhão, M., Nogueira, M., et al. (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2022.2035309 · Cited by 20
Mountz, J. D., Gao, M., Ponder, D., Liu, S., Sun, C., Alduraibi, F. K., Sullivan, K. A., Pat, B., Dell’Italia, L. J., & Hsu, H. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109130 · Cited by 24
Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
Menzella, F., Ballarin, A., Sartor, M., Floriani, A. F., Corsi, L., Dartora, C., Tonin, S., & Romagnoli, M. (2022) · Journal of International Medical Research · doi:10.1177/03000605221133689 · Cited by 24
Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin
Leung, D. Y. M., Bissonnette, R., Kreimer, S. D., Berdyshev, E. V., Bafna, S., Lyubchenko, T. A., Richers, B. N., Garcia, S. L., Ramirez-Gama, M. A., Hall, C. F., et al. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.03.020 · Cited by 22
Houser, A. E., Kazmi, A., Nair, A., & Ji, A. L. (2023) · JID Innovations · doi:10.1016/j.xjidi.2023.100198 · Cited by 25
“Not surprisingly, therapeutic responses directed at a single axis, such as the IL-4/-13 pathway blocking antibodies dupilumab and tralokinumab, show room for improvement, with response rates of w40% or less (Simpson et al., 2016; Wollenberg et al., 2021).”
BackgroundDupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks
Paganini, C., Talamonti, M., Maffei, V., Raimondo, C. D., Bianchi, L., & Galluzzo, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030878 · Cited by 20
“REVIEW 5 of 13 With regard to the safety pro fi le of dupilumab, the most common side e ff ects re-ported in the literature are reactions at the injection site and episodes of conjunctivitis [9].”
BackgroundInfluentialA Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis
Waligóra-Dziwak, K., Dańczak‐Pazdrowska, A., & Jenerowicz, D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144001 · Cited by 23
“Incidence of allergic conjunctivitis as well as conjunctivitis with an unspecified cause was elevated in the groups treated with dupilumab compared to the groups receiving placebo [18].”
BackgroundChokevittaya, P., Jirattikanwong, N., Thongngarm, T., Phinyo, P., & Wongsa, C. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.08.054 · Cited by 24
American Academy of Dermatology Annual Meeting: Orlando, FL, USA, 3–7 March 2017
Fraser, K. A. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0273-1 · Cited by 20
“In the phase 3 SOLO 1 and 2 trials, Eczema Area And Severity Index (EASI)-75 response was achieved in 53 and 48% of dupilumab recipients and 15 and 12% of placebo recipients, respectively [20].”
BackgroundNovel Therapeutic Approaches to Atopic Dermatitis
Osinka, K., Dumycz, K., Kwiek, B., & Feleszko, W. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0487-1 · Cited by 19
Towards personalized treatment in atopic dermatitis
van der Schaft, J., Thijs, J. L., Garritsen, F. M., Balak, D., & de Bruin-Weller, M. S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1583204 · Cited by 19
“inadequate response to topical corticosteroid treatment [1].”
Tips and Tricks for Controlling Eczema
Raveendran, R. (2019) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2019.07.006 · Cited by 20
Current and emerging biologic therapies for allergic rhinitis and chronic rhinosinusitis
Licari, A., Castagnoli, R., Filippo, M. D., Foiadelli, T., Tosca, M. A., Marseglia, G. L., & Ciprandi, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1729350 · Cited by 23
“Recently, anti-IgE has been approved also for chronic spontaneous urticaria resistant to antihistaminic therapy [54] and other mAbs targeting type 2 inflammation have been approved and are available now for patients with severe eosinophilic asthma [55–57], atopic dermatitis [58,59], and chronic spontaneous urticaria […”
BackgroundAki, A., Tanaka, K., Nagaoka, N., Kimura, T., Baba, D., Onodera, Y., Wada, T., Maeda, H., Nakanishi, T., Agatsuma, T., et al. (2020) · FASEB BioAdvances · doi:10.1096/fba.2020-00008 · Cited by 19
Su, C., & Tseng, H. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.03.007 · Cited by 19
“Dupilumab, a human monoclonal antibody that blocks the shared receptor subunit of IL-4 and IL-13, mitigates the signs and symptoms of atopic dermatitis.(4,5) Previously, 2 case reports have demonstrated the substantial improvements of atopic dermatitis following the injection of dupilumab.”
BackgroundThe emerging role of dupilumab in dermatological indications
Napolitano, M., Guida, A. D., Nocerino, M., Fabbrocini, G., & Patruno, C. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1907341 · Cited by 21
“In AD patients, it is able to reduce the inflammatory skin molecular signature and induce a significant decrease in disease severity, with a subsequent improvement in the quality of life [8,14,15].”
BackgroundCorren, J., Katelaris, C. H., Castro, M., Maspero, J. F., Ford, L. B., Halpin, D. M. G., Rice, M. S., Radwan, A., Deniz, Y. M., Rowe, P. J., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04498-2020 · Cited by 20
A new era has begun: Treatment of atopic dermatitis with biologics
Stölzl, D., Weidinger, S., & Drerup, K. A. (2021) · Allergologie select · doi:10.5414/alx02259e · Cited by 20
Kosloski, M. P., Guttman‐Yassky, E., Cork, M. J., Worm, M., Nahm, D., Zhu, X., Ruddy, M. K., Harel, S., Kamal, M. A., Goulaouic, H., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.13874 · Cited by 22
“19 In conclusion, these studies demonstrate that both itepekimab monotherapy and the combination of itepe-kimab and dupilumab were well tolerated in adults with moderate- to-severe AD, with no ADA response seen to itepekimab.”
InfluentialSelf-citationHwang, A., Kechter, J. A., Do, T. H., Hughes, A. N., Zhang, N., Li, X., Wasikowski, R., Brumfiel, C. M., Patel, M. H., Boudreaux, B. W., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179436 · Cited by 29
Infections in Patients with Atopic Dermatitis and the Influence of Treatment
Napolitano, M., Esposito, M., Fargnoli, M. C., Girolomoni, G., Romita, P., Nicoli, E., Matruglio, P., & Foti, C. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00917-z · Cited by 24
Calabrese, L., Cartocci, A., Rubegni, P., French, L. E., & Kendziora, B. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20617 · Cited by 19
“23,24 Third, different methods for handling missing data have been applied by the included trials for the HiSCR50 efficacy endpoint.”
Alcohol-induced facial flushing in a patient with atopic dermatitis treated with dupilumab
Igelman, S., Na, C. H., & Simpson, E. L. (2020) · JAAD Case Reports · doi:10.1016/j.jdcr.2019.12.002 · Cited by 19
“She was subsequently started on dupilumab for her refractory AD.”
BackgroundInfluentialSelf-citationCalzavara‐Pinton, P., on behalf of RADAR Group, Fortina, A. B., Bonamonte, D., Marseglia, G. L., del Giudice, M. M., Musarra, A., Nettis, E., Neri, I., Patruno, C., et al. (2021) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.20.06654-7 · Cited by 24
Dolinger, M. T., Rolfes, P. S., Spencer, E. A., Stoffels, G. J., Dunkin, D., & Dubinsky, M. C. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac055 · Cited by 19
Paller, A. S., Siegfried, E. C., Cork, M. J., Wollenberg, A., Arkwright, P. D., González, M. E., Lockshin, B., Chen, Z., Bansal, A., Levit, N. A., et al. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00553-8 · Cited by 22
Self-citationPaller, A. S., Silverberg, J. I., Cork, M. J., Guttman‐Yassky, E., Lockshin, B., Irvine, A. D., Kim, M. B., Kabashima, K., Chen, Z., Lü, Y., et al. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.6192 · Cited by 22
Self-citationVeverka, K. A., Thng, S. T. G., Silverberg, J. I., Armstrong, A. W., Menezes, J., Kaoukhov, A., & Blauvelt, A. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.10.026 · Cited by 23
Self-citationAbrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
Edwards, S. J., Karner, C., Jhita, T., Barton, S., Marceniuk, G., Yiu, Z. Z. N., & Wittmann, M. (2023) · Health Technology Assessment · doi:10.3310/lexb9006 · Cited by 25
Simpson, E. L., de Bruin-Weller, M. S., Hong, H., Staumont-Sallé, D., Blauvelt, A., Eyerich, K., Gooderham, M., Shahriari, M., Mallbris, L., Atwater, A. R., et al. (2024) · Dermatology and Therapy · doi:10.1007/s13555-024-01158-4 · Cited by 23
Self-citationAn update on the topical and oral therapy options for treating pediatric atopic dermatitis
Glines, K. R., Stiff, K. M., Freeze, M. E., Cline, A. E., Strowd, L. C., & Feldman, S. R. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561868 · Cited by 19
“Reduced pruritus and inflammation improved the quality of life in affected patients [57].”
BackgroundThyssen, J. P., Berents, T. L., Bradley, M., Deleuran, M. S., Grimstad, Ø., Korhonen, L., Langeland, T., Särnhult, T., Thomsen, S. F., Thune, T., et al. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3369 · Cited by 20
“Systemic treatments approved for the treatment of moderate-to-severe adult AD include cyclosporine-A, prednisolone (approved for AD in Norway) and the biologic dupilumab (15).”
BackgroundSelf-citationBiologics for atopic diseases: Indication, side effect management, and new developments
Jappe, U., Beckert, H., Bergmann, K., Gülşen, A., Klimek, L., Philipp, S., Pickert, J., Rauber, M. M., Renz, H. E., Taube, C., et al. (2021) · Allergologie · doi:10.5414/alx02197e · Cited by 24
“…Agency (EMA) at the end of 2017 for adults with moderate to severe atopic dermatitis after an extensive study program with two success - ful placebo-controlled phase 3 studies [30], a long-term study over 1 year in which topical corticosteroids were allowed to be used in the comparative arm [31].”
BackgroundSelf-citationA review of IL-36: an emerging therapeutic target for inflammatory dermatoses
Hwang, J., Rick, J. W., Hsiao, J. L., & Shi, V. Y. (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2022.2067819 · Cited by 21
“IL-36 has been shown to induce the production of IL-4 and IL-13, which are important drivers of Th2 inflammation in atopic dermatitis (AD) (35,36), in bone marrowderived dendritic cells and cultured splenocytes (14).”
BackgroundLangley, R. G., Gherardi, G., Coleman, A., Ardeleanu, M., Rodríguez-Marco, A., Levy, S., Bansal, A., Chen, Z., Rossi, A. B., Shumel, B., et al. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00952-w · Cited by 18
Self-citationNeuroimmune Circuits in Allergic Diseases
Cai, H., Zhu, X., & Sokol, C. L. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082423-032154 · Cited by 19
Guttman‐Yassky, E., Simpson, E. L., Bissonnette, R., Eichenfield, L. F., Kabashima, K., Luna, P. C., Hercogova, J. T., Spelman, L. J., Worm, M., Esfandiari, E., et al. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2464528 · Cited by 21
“…blockade, is often the first biologic treatment used in many countries, but only 36% to 38% of 671 patients receiving dupilumab in phase 3 trials achieved the Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) and reduction of ≥ 2 points from baseline at week 16 [18].”
Self-citationAdverse effects of biologics used to treat asthma
Sitek, A. N., Chiarella, S. E., & Pongdee, T. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251319175 · Cited by 19
Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review
Wang, Y., Wan, Z., Jin, R., Xu, T., Ouyang, Y., Wang, B., Ruan, G., & Bai, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108517 · Cited by 19
Kojanová, M., Tanczosová, M., Štrosová, D., Cetkovská, P., Fialová, J., Doležal, T., Machovcová, A., Gkalpakiotis, S., & on behalf of the BIOREP Study Group (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2022.2043545 · Cited by 19
“In clinical trials and real-world studies, other reported adverse events, namely, viral infections, headaches, injection site reactions, arthralgia, and eosinophilia, occurred in small numbers (8,9,11,13,17,22,25).”
BackgroundMethodResultInfluentialLaquer, V. T., Parra, V., Lacour, J. ‐., Takahashi, H., Knorr, J., Okragly, A. J., James, D. E., Sims, J. T., Chang, C.-Y., Chao, J., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21631 · Cited by 20
Self-citationTreatment options for moderate to severe atopic dermatitis
Wallace, D. V. (2022) · Allergy and Asthma Proceedings · doi:10.2500/aap.2022.43.220076 · Cited by 20
Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer
Tanczosová, M., Hugo, J., & Gkalpakiotis, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031191 · Cited by 17
“Patients with a history of malignancy were generally excluded from dupilumab clinical trials [13,16].”
BackgroundSiegfried, E. C., Cork, M. J., Katoh, N., Zhang, H., Chuang, C., Thomas, R. B., Rossi, A. B., Cyr, S. L., & Zhang, A. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00791-7 · Cited by 22
Self-citationPatient preferences for atopic dermatitis treatments: a discrete choice experiment
Kwatra, S. G., Lio, P., Weidinger, S., Calimlim, B., Ladizinski, B., Vigna, N., Botha, W., & Mansfield, C. A. (2023) · Journal of Dermatological Treatment · doi:10.1080/09546634.2023.2222201 · Cited by 19
“Despite the widely appreciated impact of moderate-to-severe AD, some systemic approaches do not fully resolve pruritus or provide skin clearance (10).”
BackgroundRenert‐Yuval, Y., DUCA, E. D., Arents, B. W. M., Bissonnette, R., Drucker, A. M., Flohr, C., Guttman‐Yassky, E., Hijnen, D., Kabashima, K., Leshem, Y. A., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19506 · Cited by 18
“53 These therapeutic outcomes were also reported as meaningful percentage MCIDs, regardless of baseline AD severity.”
BackgroundSelf-citationKappa opioid agonists in the treatment of itch: just scratching the surface?
Beck, T. C., Wilson, E. M., Wilkes, E., Lee, L. W., Norris, R. A., & Valdebran, M. (2023) · Itch · doi:10.1097/itx.0000000000000072 · Cited by 22
“These medications, except for dupilu-mab, gabapentin, and pregabalin, have the potential for signi fi cant side effects and thus should be used conservatively [29 – 36] .”
MethodCorso, E. D., Montuori, C., Baroni, S., Mastrapasqua, R. F., Porru, D. P., D'Auria, L. M., D’Agostino, G., Penazzi, D., Maio, G. D., Onori, M. E., et al. (2023) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-023-08417-8 · Cited by 20
“The same transitory phenomenon has been described in RCTs for the treatment of patients with CRSwNP and atopic dermatitis [4, 5, 16, 18].”
Caminati, M., Micheletto, C., Norelli, F., Olivieri, B., Ottaviano, G., Padoan, R., PIACENTINI, G. L., Schiappoli, M., Senna, G., & Menzella, F. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2304556 · Cited by 22
“Dupilumab is currently used in the treatment of a variety of T2 conditions, including severe asthma [10,11], nasal polyps [12,13], atopic dermatitis [14–16] and, more recently, eosino-philic esophagitis [17].”
BackgroundLavin, L., Dusza, S. W., & Geller, S. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.06.1272 · Cited by 18
Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
Blauvelt, A., Guttman‐Yassky, E., Lynde, C. W., Khattri, S., Schlessinger, J., Imafuku, S., Tada, Y., Morita, A., Wiseman, M., Kwiek, B., et al. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.2131 · Cited by 21
Self-citationRamonell, R. P., Gauthier, M. C., Ray, A., & Wenzel, S. E. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-070323-103158 · Cited by 23
“IL-4R α therapy may be most effective in markedly T2-high patients (adult and pediatric) with elevated levels of both FeNO and eosinophils, especially those with comorbid T2 disease where dupilumab has shown clinical efficacy such as CRSwNP (101) or atopic dermatitis (102).”
Investigational drugs for atopic dermatitis
Hon, K. E., Leung, A. K. C., Leung, T. N., & Lee, V. W. Y. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1494723 · Cited by 18
Tofte, S. J., Papp, K. A., Sadick, N. S., Bohnert, K. L., Simpson, E. L., Thaçi, D., Bieber, T. R. M., Blauvelt, A., Sofen, H. L., Gooderham, M., et al. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000088 · Cited by 18
Self-citationDupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history
Corren, J., Castro, M., Ford, L. B., Bernstein, J. A., Jayawardena, S., Maroni, J. M., Rowe, P., Amin, N., Pirozzi, G., Graham, N. M. H., et al. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.04.028 · Cited by 18
Self-citationDupilumab for atopic dermatitis: evidence to date
Rodrigues, M. A., Nogueira, M., & Torres, T. R. (2019) · Giornale Italiano di Dermatologia e Venereologia · doi:10.23736/s0392-0488.19.06417-4 · Cited by 22
Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes
Brooks, G. D. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s192392 · Cited by 18
“Three trials of dupilumab were performed in patients with moderate-to-severe atopic dermatitis not controlled by topical corticosteroids.(4,9,10) Subjects received 600 mg dupilumab”
BackgroundThyssen, J. P., Heegaard, S., Ivert, L. U., Remitz, A., Agner, T., de Bruin-Weller, M. S., Huldt-Nystrøm, T., Korhonen, L., Ivert, L. U., Leinonen, P., et al. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3629 · Cited by 18
“Finally, the pathogenesis of dupilumabassociated conjunctivitis is not yet fully understood (24, 29, 30) and we did not include discussions on potential exposures that could influence decisions, e.”
BackgroundNakahara, T., Izuhara, K., Onozuka, D., Nunomura, S., Tamagawa‐Mineoka, R., Masuda, K., Ichiyama, S., Saeki, H., Kabata, Y., Abe, R., et al. (2020) · Medicine · doi:10.1097/md.0000000000022043 · Cited by 21
“From previous phase 3 trials,([7]) since it is assumed that approximately 25% of enrolled patients with dupilumab treatment will discontinue the treatment, a plan was set to enroll more than 130 subjects and perform data analysis of at least 100 subjects.”
BackgroundInfluentialSelf-citationNapolitano, M., Ferrillo, M., Patruno, C., Scalvenzi, M., D’Andrea, M., & Fabbrocini, G. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00505-z · Cited by 18
Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study
Zhou, B., Peng, C., Li, L., Liu, R., Zhu, L., Chen, X., & Li, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.838030 · Cited by 22
“As mentioned above, the primary (EASI 75) or secondary (NRS peak pruritus improvement ≥4 or DLQI improvement ≥4) endpoints were concerned during treatment (17).”
BackgroundDupilumab for atopic dermatitis
Strowd, L. C., & Feldman, S. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31192-3 · Cited by 18
New and emerging therapies for paediatric atopic dermatitis
Vakharia, P. P., & Silverberg, J. I. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(19)30030-6 · Cited by 18
Self-citationIs there still a role for UV therapy in itch treatment?
Legat, F. J. (2019) · Experimental Dermatology · doi:10.1111/exd.14011 · Cited by 18
Neuroimmune mechanisms of type 2 inflammation in the skin and lung
Tamari, M., & Ver Heul, A. M. (2025) · Allergology International · doi:10.1016/j.alit.2025.02.001 · Cited by 17
Highlights in immune response, microbiome and precision medicine in allergic disease and asthma
Sokołowska, M., & Akdiş, C. A. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.10.009 · Cited by 18
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic
Kearns, D. G., Uppal, S., Chat, V. S., & Wu, J. J. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.06.015 · Cited by 17
“Nasopharyngitis was the most commonly reported infection among all treatment groups (Table I).(3) Furthermore, the conclusion in all 3 trials was that the rate of infection was not increased in dupilumab-treated patients compared with placebo.”
Shin, H., Lee, S. H., Yoon, H. S., Heo, J. H., Lee, S. B., Byun, J. W., Shin, J., Cho, Y., Chung, E., Jeon, M., et al. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15928 · Cited by 18
Atopic Eczema: Pathophysiological Findings as the Beginning of a New Era of Therapeutic Options
Traidl, S., Werfel, T., & Traidl‐Hoffmann, C. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_492 · Cited by 22
Adverse events associated with dupilumab in the World Health Organization pharmacovigilance database
Bettuzzi, T., Drucker, A. M., Staumont-Sallé, D., Bihan, K., Lebrun‐Vignes, B., & Sbidian, É. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.09.050 · Cited by 17
Costanzo, A., on behalf of Italian AD Study Group, AMERIO, P., ASERO, R., Chiricozzi, A., CORAZZA, M., CRISTAUDO, A., Cusano, F., Ferrucci, S. M., Nettis, E., et al. (2021) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.21.07129-2 · Cited by 20
Busse, W. W., Castro, M., & Casale, T. B. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.10.015 · Cited by 23
Ahmad, J. G., Marino, M. J., & Luong, A. (2022) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2022.09.014 · Cited by 19
Kim, H.-O. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01421-2 · Cited by 19
Chen, Q., Cui, L., Hu, Y., Chen, Z., Gao, Y., & Shi, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22014 · Cited by 22
Interdisziplinäre Handlungsempfehlung bei Dupilumab-assoziierten entzündlichen Augenerkrankungen
Wohlrab, J., Wollenberg, A., Reimann, H., Pleyer, U., & Werfel, T. (2018) · Der Hautarzt · doi:10.1007/s00105-018-4316-1 · Cited by 18
Self-citationLeshem, Y. A., Bissonnette, R., Paul, C. F., Silverberg, J. I., Irvine, A. D., Paller, A. S., Cork, M. J., & Guttman‐Yassky, E. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15480 · Cited by 18
Self-citationFacial erythema after the treatment of dupilumab in SLE patient
Jang, D. H., Lee, J. I., Bae, J. Y., Jung, H. J., Park, M. Y., & Ahn, J. (2020) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-020-00458-6 · Cited by 17
“The erythema and desquamation after treatment with dupilumab were not reported in previous clinical trials [1].”
BackgroundQi, H.-J., & Li, L. (2021) · BioMed Research International · doi:10.1155/2021/5528372 · Cited by 18
Ariëns, L. F. M., Bakker, D. S., Spekhorst, L. S., van der Schaft, J., Thijs, J. L., Haeck, I. M., Flinterman, A. E., Kamsteeg, M., Schuttelaar, M. L. A., & de Bruin-Weller, M. S. (2021) · Acta Dermato Venereologica · doi:10.2340/00015555-3886 · Cited by 17
Metadata
- Authors
- Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., Kingo, K., Worm, M., Poulin, Y., Wollenberg, A., Soo, Y., Graham, N. M. H., Pirozzi, G., Akinlade, B., Staudinger, H., Mastey, V., Eckert, L., Gadkari, A., Stahl, N., Yancopoulos, G. D., & Ardeleanu, M.
- Affiliations
- University of Bonn (DE)
- Northwestern University (US)
- ORCID
- Simpson, Eric L.
- Bieber, Thomas
- Beck, Lisa A.
- Blauvelt, Andrew
- Cork, Michael J.
- Silverberg, Jonathan I.
- Deleuran, Mette
- Kataoka, Yoko
- Lacour, Jean-Philippe
- Kingo, Külli
- Worm, Margitta
- Poulin, Yves
- Wollenberg, Andreas
- Soo, Yuhwen
- Graham, Neil M.H.
- Pirozzi, Gianluca
- Akinlade, Bolanle
- Staudinger, Heribert
- Eckert, Laurent
- Stahl, Neil
- Ardeleanu, Marius
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-15
- Volume
- 375
- Issue
- 24
- Pages
- 2335-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2524051065
- Cited by
- 2,110
- References
- 38
- Citations by year
- 2026: 183 · 2025: 219 · 2024: 227 · 2023: 239 · 2022: 218 · 2021: 238 · 2020: 244 · 2019: 236 · 2018: 160 · 2017: 130 · 2016: 8
- FWCI
- 211.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- Scopus (Elsevier) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- ab, atopic dermatitis, IL-4 receptor alpha, IL-13, IL-4, type 2 cytokines, monoclonal antibodies, subcutaneous administration, dosing frequency, Investigator's Global Assessment, Eczema Area and Severity Index, pruritus, injection site reactions, conjunctivitis, quality of life
- MeSH terms
- Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Dermatitis, Atopic, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Nasopharyngitis, Pruritus, Quality of Life, Interleukin-4, Interleukin-13, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.